Introduction
Treatment regimens are becoming increasingly complex, with a greater risk of drug interactions. Drug-drug interactions can cause significant patient harm. This is either due to drug toxicity or loss of efficacy. For example, voriconazole 1 and clarithromycin increase simvastatin concentrations risking rhabdomyolysis, while rifampicin decreases the anticoagulant effect of warfarin. Sometimes interacting drugs are intentionally co-prescribed, for example diltiazem can be used to increase ciclosporin concentrations. Drug-drug interactions can also occur with complementary medicines.
Clinicians should use the available drug-drug interaction resources, but be aware that, although advice may be similar from each resource, discrepancies also occur. It is important that potential drug-drug interactions are evaluated for their clinical significance and relevance to each patient. To identify interactions it is first necessary to have an accurate list of the patient's prescription, complementary and over-the-counter medicines. Drugs given by other routes, such as topical and inhaled, should also be considered.
Mechanisms
The mechanisms of drug-drug interactions vary. 2, 3 Clinicians need to understand the drug's pharmacology including metabolic pathways to determine both pharmacodynamic (altered effect) and pharmacokinetic (altered concentration) interactions. It can be particularly complex to assess the clinical significance of interactions from multiple drugs which each have a potentially additive effect on
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Some of the information used to develop drug-drug interaction resources includes:
• Australian and international product information
• primary literature (case reports and clinical papers)
• guidance from international regulatory bodies, such as the Therapeutic Goods Administration (TGA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Gaps
Depending on the information used and their editorial criteria, resources may give different advice about interactions especially when assigning clinical significance. In some cases, interaction advice may be lacking entirely. These gaps can occur due to variations in product information, or when the metabolism of a drug is not well defined. A particularly challenging area for advice about drug-drug interactions is with new drugs, such as enzalutamide (Table 2) , and older re-purposed drugs, such as pristinamycin. Clinical experience of these drugs in combination with other drugs is limited. Sometimes interaction information is extrapolated from other drugs in the same class or those with similar metabolism. Interactions may not be included in the resources until they have been reported to the TGA or published as case reports.
The available resources usually provide information about interactions between two drugs, however patients may be taking multiple drugs with many potential interactions. There is no resource currently available that can provide information about the overall risk of interactions with different combinations of drugs. Medicines information pharmacists may be able to provide advice in these cases.
Drug interactions -search strategy
When looking for information, clinicians are strongly encouraged to have access to the online interaction checking tool in the AMH. Similar tools in MIMS or AusDI are also valuable. For newer drugs, those with complex metabolism or for unusual drug-drug combinations, there may be a need to refer to multiple resources.
In order to predict the potential for a drug-drug interaction, cytochrome tables, such as in the AMH or Flockhart, are useful, along with the mechanism of action given in the product information. For specific drug classes, free access to specialised resources is available ( 
Electronic decision support
Drug interaction alerts are included as decision support at the point of care in electronic prescribing and dispensing systems. For example, some interaction alerts in general practice software are referenced to the MIMS interaction checker.
There are concerns that systems generate so many warnings that there is a risk of alert fatigue. This has led to calls in the USA, particularly in the hospital environment, to standardise the information in electronic systems, with the development of methods to filter out unimportant drug-drug interaction alerts. 8 However, an international or local consensus on standardisation has not yet been reached.
8,9
Real-world data
For new drugs there may be few clinical trials or case reports of drug-drug interactions in 'realworld' conditions involving patients with multiple comorbidities taking many drugs. For example, many resources about antiretroviral drug-drug interactions are based on theoretical information, so the clinical relevance in everyday practice is unknown. A Spanish group has therefore established a website that allows clinicians to submit cases of antiretroviral drug-drug interactions. 10 Clinicians are encouraged to publish case reports of new or unusual drug-drug interactions, as these are valuable in informing clinical practice. Reporting suspected drug and vaccine interactions to the Therapeutic Goods Administration is also encouraged via the TGA Adverse Event Management System.
Conclusion
Clinicians should consult drug-drug interaction information, evaluate it and consider its relevance for their patient. For new drugs or when information is inconsistent or absent, it may be necessary to refer to multiple interaction resources or seek expert advice, for example from a medicines information pharmacist. 
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Although no interaction found, need to consider pharmacokinetic and background information provided, which suggests ↓oxycodone. Consider an alternative or monitor pain relief and adjust oxycodone dose Although no interaction found, need to consider pharmacokinetic and background information provided, which suggests ↓mirtazapine. Possible additive seizure risk Although no interaction found, need to consider pharmacokinetic and background information provided and extrapolate from other potent CYP3A4 inducers. ↓rivaroxaban
MIMS Interaction Database
No interaction listed No interaction listed No interaction listed
Stockley's Drug Interactions
Theoretical evidence predicts ↓oxycodone
Theoretical evidence predicts ↓mirtazapine
Theoretical evidence predicts ↓rivaroxaban, but confusing as no information to suggest enzalutamide's effect on P-glycoprotein#
Lexicomp Drug Interactions
Risk Rating D: need to consider dose modification as ↓oxycodone Risk Rating D: need to consider dose modification as ↓mirtazapine
Risk Rating X: avoid -see comments
Micromedex Drug Interactions
Major interaction. 
Notes
Enzalutamide, an anti-androgen for metastatic castration-resistant prostate cancer, will be increasingly seen in the community. It is an unrecognised, yet major contributor to drug interactions and has a particularly complex metabolism. It is a potent CYP3A4 inducer, moderate CYP2C9 and CYP2C19 inducer, but its effect on P-glycoprotein is conflicting in the manufacturer's information. This, combined with the limited published reports of clinical outcomes from drug interactions to date, has resulted in variation or, in some cases, an absence of reporting of drug-drug interactions. In addition, the extended half-life (approximate mean 6 days) makes drug-drug interactions difficult to predict, with maximum induction potential occurring up to one month from starting enzalutamide, and effects on enzymes continuing for at least one month after cessation. Management of anticoagulation in patients taking enzalutamide is particularly challenging and input from a haematologist is recommended. Enzalutamide has complex metabolism:
• substrate CYP2C8 (major), CYP3A4 (minor)
• induces CYP3A4 (potent), CYP2C9 and CYP2C19 (moderate)
• product information says in vitro enzalutamide inhibits P-glycoprotein but it also says it may act as an inducer 
